Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCAT 2023 | The future of SCD and thalassemia HSCT: partially matched donors

Lawrence Faulkner • 26 Oct 2023
ASCAT 2023
Non-Malignant Sickle Cell Disease Thalassemia

Lawrence Faulkner, MD, Cure2Children Foundation, Florence, Italy, highlights the potential for haploidentical hematopoietic stem cell transplantation (HSCT) as a cost-effective and accessible option for treating sickle cell disease (SCD) and thalassemia. This interview was held at the 18th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) 2023, held in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Lawrence Faulkner

1:08
Bone Marrow Quality Index to assess the safety of HSCT in thalassemia
Lawrence Faulkner • 26 Oct 2023
0:54
The barriers to gene therapy implementation for treating SCD in low- and middle-income countries
Lawrence Faulkner • 26 Oct 2023
2:30
Cure2Children: delivering transplant therapy for SCD and thalassemia in developing countries
Lawrence Faulkner • 26 Oct 2023

Related Videos

2:01
The MDT in the new era of gene therapy for hemoglobinopathies
Mattia Algeri • 15 Apr 2024
2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals